ATE175203T1 - Sulfatierte glykolipide, die eine galaktose-3-0- sulfate-gruppierung enthalten, und spezifische fänger für diese für die verwendung in der prophylaxe oder therapie der prädiabetis, diabetis und/oder damit zusammenhängender komplikationen in einem individuum - Google Patents

Sulfatierte glykolipide, die eine galaktose-3-0- sulfate-gruppierung enthalten, und spezifische fänger für diese für die verwendung in der prophylaxe oder therapie der prädiabetis, diabetis und/oder damit zusammenhängender komplikationen in einem individuum

Info

Publication number
ATE175203T1
ATE175203T1 AT92910435T AT92910435T ATE175203T1 AT E175203 T1 ATE175203 T1 AT E175203T1 AT 92910435 T AT92910435 T AT 92910435T AT 92910435 T AT92910435 T AT 92910435T AT E175203 T1 ATE175203 T1 AT E175203T1
Authority
AT
Austria
Prior art keywords
individual
galactose
methods
sulfate
prediabetis
Prior art date
Application number
AT92910435T
Other languages
English (en)
Inventor
Karsten Buschard
Original Assignee
A & Science Invest Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A & Science Invest Ab filed Critical A & Science Invest Ab
Application granted granted Critical
Publication of ATE175203T1 publication Critical patent/ATE175203T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT92910435T 1991-05-07 1992-05-07 Sulfatierte glykolipide, die eine galaktose-3-0- sulfate-gruppierung enthalten, und spezifische fänger für diese für die verwendung in der prophylaxe oder therapie der prädiabetis, diabetis und/oder damit zusammenhängender komplikationen in einem individuum ATE175203T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK91846A DK84691D0 (da) 1991-05-07 1991-05-07 Visse glycolipider og specifikke catchere for disse til anvendelse ved profylaxe eller terapi af diabetes, og/eller dermed forbundne komplikationer samt anvendelse af saadanne glycolipider til detektion af oe-celle-antistoffer (ica) i et individ og anvendelse af saadanne catchere til detektion af langerhans-oe-celler i pancreas-praeparater

Publications (1)

Publication Number Publication Date
ATE175203T1 true ATE175203T1 (de) 1999-01-15

Family

ID=8098211

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92910435T ATE175203T1 (de) 1991-05-07 1992-05-07 Sulfatierte glykolipide, die eine galaktose-3-0- sulfate-gruppierung enthalten, und spezifische fänger für diese für die verwendung in der prophylaxe oder therapie der prädiabetis, diabetis und/oder damit zusammenhängender komplikationen in einem individuum

Country Status (9)

Country Link
US (1) US5827828A (de)
EP (1) EP0584175B1 (de)
JP (1) JP3222465B2 (de)
AT (1) ATE175203T1 (de)
AU (1) AU1788892A (de)
DE (1) DE69228061T2 (de)
DK (2) DK84691D0 (de)
ES (1) ES2125898T3 (de)
WO (1) WO1992019633A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580858A (en) * 1991-06-10 1996-12-03 Alberta Research Council Immunosuppressive and tolerogenic modified Lewisx compounds
US5663151A (en) * 1994-03-04 1997-09-02 Bristol-Myers Squibb Company Sulfated α-glycolipid derivatives as cell adhesion inhibitors
CA2142153A1 (en) * 1994-03-04 1995-09-05 Jacques Banville Sulfated .beta.-glycolipid derivatives as cell adhesion inhibitors
US5686426A (en) 1994-11-17 1997-11-11 Bristol-Myers Squibb Company Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors
SE9601817D0 (sv) * 1996-05-13 1996-05-13 Karsten Buschard Novel glycolipid complexex and their uses
JP3495740B2 (ja) * 1997-04-10 2004-02-09 麒麟麦酒株式会社 α−グリコシルセラミドを含有するＮＫＴ細胞活性化剤
US6492337B1 (en) 1997-12-30 2002-12-10 A+ Science Ab Galactosylceramide, glucosylceramide, lactosylceramide, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complication
SE0000258D0 (sv) 2000-01-27 2000-01-27 A & Science Invest Ab Pharmaceutical preparation and method for treatment of diabetes
EP1437358B1 (de) 2001-08-16 2006-10-18 Daiichi Asubio Pharma Co., Ltd. Neues glykolipid, und heilmittel für autoimmunerkrankungen, das dieses als wirkstoff enthält
EP2040541B1 (de) * 2006-06-30 2016-03-23 The Scripps Research Institute Hilfsstoffe und verwendungsverfahren
FR2926972B1 (fr) * 2008-02-05 2011-03-11 Technologia Appareil de diagnostic precoce du syndrome du canal carpien et procede et dispositif d'acquisition de l'information relative a la sensibilite cutanee du doigt du patient

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288706A (en) * 1987-12-25 1994-02-22 Mitsui Toatsu Chemicals, Incorporated Medicament for prevention and remedy of diseases of the pancreas and others

Also Published As

Publication number Publication date
US5827828A (en) 1998-10-27
DE69228061T2 (de) 1999-05-27
JPH06506943A (ja) 1994-08-04
JP3222465B2 (ja) 2001-10-29
ES2125898T3 (es) 1999-03-16
DK0584175T3 (da) 1999-08-30
EP0584175B1 (de) 1998-12-30
DE69228061D1 (de) 1999-02-11
AU1788892A (en) 1992-12-21
DK84691D0 (da) 1991-05-07
WO1992019633A1 (en) 1992-11-12
EP0584175A1 (de) 1994-03-02

Similar Documents

Publication Publication Date Title
Ashbrook et al. Medium chain fatty acid binding to human plasma albumin
ATE175203T1 (de) Sulfatierte glykolipide, die eine galaktose-3-0- sulfate-gruppierung enthalten, und spezifische fänger für diese für die verwendung in der prophylaxe oder therapie der prädiabetis, diabetis und/oder damit zusammenhängender komplikationen in einem individuum
Olsen et al. The intestinal brush border membrane in diabetes: studies of sucrase-isomaltase metabolism in rats with streptozotocin diabetes
CA2005300A1 (en) Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
Carter et al. Streptothricin. I. Preparation, Properties and Hydrolysis Products1
Cheng High-performance liquid chromatographic analysis of galactosamine, glucosamine, glucosaminitol, and galactosaminitol
Nordlind Further studies on the ability of different metal salts to influence the DNA synthesis of human lymphoid cells
CA2072368A1 (en) Methods for diagnosing human influenza and 4-position modified chromogenic n-acetylneuraminic acid substrates for use therein
Lindberg et al. Urinary excretion of chromium in chromeplaters after discontinued exposure
Alessio et al. Free erythrocyte protoporphyrin as an indicator of the biological effect of lead in adult males: III. Behavior of free erythrocyte protoporphyrin in workers with past lead exposure
Chuong et al. The MMPI as an aid in evaluating patients with premenstrual syndrome
Lorente et al. A simple and reproducible method to evaluate granulocyte adherence
Whitehead et al. Metabolites of phenylalanine in the urine of children with kwashiorkor
GR980300023T1 (en) Means for treating auto-immune diseases and method of treatment
Wang et al. Plasma arginase concentration measured by an enzyme-linked immunosorbent assay (ELISA) in normal adult population
Wu et al. Effect of platelet activation on the platelet surface sialic acid
Panush et al. Effects of acetaminophen on normal human peripheral blood lymphocytes: enhancement of mitogen-and antigen-stimulated incorporation of tritiated thymidine
Iannone et al. Taxol inhibits N-formyl-methionyl-leucyl-phenylalanine (FMLP)-induced human neutrophil polarization and H2O2 production while decreasing [3H] FMLP binding
Lettau et al. Effects of reduced temperature on the components of human lymphocyte transformation responses to antigens
Yachnin Further studies on the hemolysis of human red cells by late acting complement components
Kuller et al. The frequency of transplacental hemorrhage in patients with threatened abortions
SUNAGANE et al. Mechanism of relaxant action of papaverine. II. Differences between modes of relaxant effects of papaverine and amytal in guinea-pig taenia coli
JPS5443096A (en) Sample vessel for electrolyte analyser
Duckert Section 3 The absence of effect of the antirheumatic drug ibuprofen on Oral anticoagulation with phenprocoumon
Koldzhiev et al. Determination of 131I-triiodothyronine absorption by erythrocytes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee